生物制品革命：全球生物仿制药、BPCIA及专利之舞的格局导航

The BiologicsRevolution Navigating the Global Landscapeof Biosimilars, BPCIA, and thePatent Dance February 2026 Research The BiologicsRevolution Navigating the Global Landscapeof Biosimilars, BPCIA, and thePatent Dance Ranked as the ‘Most Innovative Indian Law Firm’ in the prestigious FT Innovative Lawyers Asia PacificAwards for multiple years. Also ranked amongst the ‘Most Innovative Asia Pacific Law Firm’ in theseelite Financial Times Innovation rankings. Disclaimer This report is a copyright of Nishith Desai Associates. No reader should act on the basis of any statementcontained herein without seeking professional advice. The authors and the firm expressly disclaim all andany liability to any person who has read this report, or otherwise, in respect of anything, and of consequencesof anything done, or omitted to be done by any such person in reliance upon the contents of this report. Contact For any help or assistance please email us onconcierge@nishithdesai.comor visit us atwww.nishithdesai.com. Authors: IPpro Team Priyadarsini Shanmugam priyadarsini.s@ipproinc.com Priya leads IPpro’s Lifesciences domain with 17 years of IP experience. She is a registered Attorney in California, US.She holds a biotechnology degree and master’s in law from UC Berkeley School of Law. She has extensive experiencewith patent firms, multinational companies, and global pharmaceutical in-house IP teams. Abhay Porwal abhay.porwal@ipproinc.com Abhay leads overall operations at IPpro with over 20 years of IP industry experience. He is a registered patent agentwith the IPO and holds a degree in electrical engineering from IIT Bombay. Contents List of Abbreviations Executive Summary Introduction - The Era of Biologics and Biosimilars5 The Developmental Cycle for Biologics and Biosimilars The Regulatory Framework for Biosimilar Approvals10 1.European Union: The Pioneer102.The US FDA’s Interchangeability113.India - “Similar Biologics”124.Canada: “High Degree of Similarity”135.China: “Totality of Evidence” Approach136.Australia: Australian Biological Name147.Other Major Markets – Japan, Korea and Brazil148.Global (ICH) Harmonization of Biosimilar Approval16 The Biologics Patent Landscape 1.The Biologics Price Competition and Innovation Act (BPCIA)232.Data Exclusivity233.The ‘Patent Dance’234.Interchangeability25 Landmark BPCIA Patent Cases & Litigation Strategies 1.Landmark BPCIA Patent Cases262.Litigation and Patent Thickets273.IPR/PGR – AIA Patent Challenges284.Biologics & Biosimilar Litigation Tactics and Market Strategy29 Biologics & Biosimilar Market Analysis and Strategies31 1.Biologics Market Revenue Trends (2022-2024)312.Biosimilar Approval Trends (2015-2024)333.Future Outlook for Biosimilars344.Biologics & Biosimilar Pricings: Divergent Impact on Adoption375.The Biosimilar Void396.Strategic Alliances and Licensing in Biosimilars: Structures & CarveOuts41 India Pharmaceutical Outlook (2026–2030)49 I.The “Big 5” Powerhouses: Establishing Global Dominance49II.High-Growth “New Entrants”50III. Other Player50IV. Market Limiters & Drivers51V.The Contribution to the Next Decade52 Three Emerging Forces are Reshaping The Landscape53Looking Forward54 Appendix: Biologics Patent Litigation Landscape55 List of Abbreviations Executive Summary The global pharmaceutical landscape is undergoing a structural transformation driven by the rapid expansionof biologics and the accelerating entry of biosimilars. This research paper provides a focused analysis of the coreregulatory, intellectual property (IP) and market dynamics shaping the global biologics (Reference ProductSponsor) and biosimilar market. It particularly focuses on the evolving regulatory frameworks across majorjurisdictions, the strategic deployment of biologics patent portfolios, and the unique litigation architectureestablished under the U.S. Biologics Price Competition and Innovation Act (BPCIA). Together, these forcesdefine market access, competition timelines, pricing outcomes, and patient availability. Biologics being complex therapeutics derived from living systems have revolutionized modern medicine byenabling highly targeted treatments for oncology, autoimmune diseases, and rare disorders. Their marketshare has expanded rapidly, accounting for over 40% of global pharmaceutical revenues and projectedto surpass small-molecule drugs by 20271. However, they remain among the most expensive therapies,creating systemic affordability challenges. Biosimilars, which are highly similar follow-on products with noclinically meaningful differences from reference biologics, offer a critical pathway for enhancing competition,improving patient access, and reducing healthcare expenditures. Despite regulatory advances, biosimilaruptake remains uneven, particularly in the United States, due largely to complex patent landscapes andlitigation barriers Prior to the BPCIA, there was not a pathway for approval of biosimilars in the US, while the EU establishe